Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201412026 Principal Investigator: Ghobadi, Armin
Title: A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma
___________________________________________________________________________________________________
 Number: 201403068 Principal Investigator: Abboud, Camille
Title: A Randomized, Open Label, Bioequivalence Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) when Administered in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
Description: This study has been designed so that we can compare mobilization with these two drugs....MORE
___________________________________________________________________________________________________
 Number: 201401080 Principal Investigator: Romee, Rizwan
Title: A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation with High Dose PT-Cy in Relapsed/Refractory AML
Description: The purpose of this research study is to look at patient's overall health status and how their disease responds to a stem cell transplant when followed with several doses of a drug called cyclophosphamide....MORE
___________________________________________________________________________________________________
 Number: 201312115 Principal Investigator: Cashen, Amanda
Title: A phase II study of melphalan HCl for injection (propylene glycol-free), combined with carmustine, etoposide, and cytarabine (BEAM regimen) for myeloablative conditioning in lymphoma patients undergoing autologous stem cell transplantation
Description: The purpose of this research study is to determine the safety, side effects, and effectiveness of a new formulation of melphalan when it is administered as part of the BEAM regimen, which is given prior to stem cell transplant. BEAM is a 4-drug chemotherapy combination using the following drugs: car...MORE
___________________________________________________________________________________________________
 Number: 201303012 Principal Investigator: Schroeder, Mark
Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Description: This research study aims to discover the side effects and highest dose of a drug called azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE
___________________________________________________________________________________________________
 Number: 201211047 Principal Investigator: Schroeder, Mark
Title: A Pilot Study of Brentuximab Vedotin for the Prevention of Graft-Versus-Host Disease (GVHD) after Mismatched Unrelated Allogeneic Stem Cell Transplantation
Description: The purpose of this research study is discover the side effects and highest dose of a drug called brentuximab vedotin that can be given when receiving other drugs to help prevent or minimize the effects of graft-versus-host disease (GVHD)....MORE
___________________________________________________________________________________________________
 Number: 201101864 Principal Investigator: Stockerl-Goldstein, Keith
Title: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Description: You may be invited to participate in a research study to treat non-Hodgkin’s lymphoma. The treatment plan consists of an autologous hematopoietic (blood) cell transplant followed by a non-myeloablative allogeneic transplantation (transplant from another individual). An autologous transplant is don...MORE
___________________________________________________________________________________________________
 Number: 201102463 Principal Investigator: Fehniger, Todd
Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE
___________________________________________________________________________________________________
 Number: BMT CTN 1203 Principal Investigator: Pusic, Iskra
Title: A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
Description: The purpose of this research study is to compare three combinations of medications to see whether one or more of them are better than the current standard of care (Tacrolimus/Methotrexate) to prevent GVHD(Graft-versus-Host Disease). These combinations of medication in this study are: Treatment Gro...MORE
___________________________________________________________________________________________________
 Number: BMT CTN 1102 Principal Investigator: Westervelt, Peter
Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Description: The purpose of this research study is to find out if a reduced-intensity transplant works better than the standard treatment for Myelodysplastic Syndrome (MDS). We also want to know how well you are able to do your normal activities after your treatment....MORE
___________________________________________________________________________________________________
 Number: BMT CTN 0903 Principal Investigator: Westervelt, Peter
Title: Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
___________________________________________________________________________________________________
 Number: 201501087 Principal Investigator: Uy, Geoffrey
Title: A Phase IIa, Multicenter, Open-label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Description: The main purpose of the study is to examine the safety and to see how well you tolerate BL-8040 when given once daily for two days, followed by five days of combined treatment with BL-8040 and Ara-C....MORE
___________________________________________________________________________________________________
 Number: 201407026 Principal Investigator: Abboud, Camille
Title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
Description: The purpose of this research study is test the safety of and how well study subjects tolerate the research study drug, MK-8228 and evaluate the effectiveness of MK-8228 in preventing cytomegalovirus (CMV)infection in patients receiving a stem cell transplant....MORE
___________________________________________________________________________________________________
 Number: 201204060 Principal Investigator: Romee, Rizwan
Title: Randomized Phase III Trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
Description: The purpose of this study is to determine if there is an increased in survival rate in patients who undergo a HCT transplantation followed by an infusion of genetically modified HSV-TK donor lymphocytes, compared to patients who have the standard HCT transplantation? with the standard infusion of he...MORE
___________________________________________________________________________________________________
 Number: BMT CTN 1202 Principal Investigator: Westervelt, Peter
Title: Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic Hematopoietic Cell Transplant (HCT)
Description: The purpose of this study is to learn more about what makes related and unrelated (allogeneic) bone marrow, blood stem cell and umbilical cord blood transplants work well....MORE
___________________________________________________________________________________________________
 Number: 201212113 Principal Investigator: Dubberke, Erik
Title: Evolution of CMV in Allogeneic Hematopoietic Cell Transplant Recipients
___________________________________________________________________________________________________